Intervention Development for Tailored Education for Aging and Cognitive Health (TEACH) for Dementia Prevention in Midlife Adults: Protocol for a Randomized Controlled Trial.


Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
16 Oct 2024
Historique:
received: 09 05 2024
accepted: 23 07 2024
revised: 22 07 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

A total of 12 modifiable risk factors account for 40% of dementia cases globally, yet population adherence to health behaviors associated with these factors is low. Midlife is a critical window for dementia prevention, as brain pathology often begins to accumulate years or decades before the onset of symptoms. Although multidomain behavioral interventions have been efficacious in reducing the risk of cognitive decline, adherence is low. Intrapersonal factors, such as health beliefs, are known mediators of the relationship between knowledge and health behavior. In keeping with stage I of the National Institutes of Health (NIH) Stage Model for Behavioral Intervention Development, this study will use mixed methods to (1) develop an enhanced health education intervention, including an explanatory method for communicating information about dementia risk and personal health beliefs, and (2) conduct a pilot randomized controlled trial (n=20 per intervention arm) over 8 weeks to assess the feasibility of delivering the enhanced intervention versus basic health education alone. Phase 1 will involve focus groups and individual qualitative interviews. Focus groups will be analyzed using (1) a descriptive framework matrix analysis and (2) interpretive data review by the research team. Individual qualitative interviews will be coded using applied thematic analysis using a phenomenographic approach. Phase 2 will involve a pilot randomized controlled trial. Proximal outcomes (measured at baseline, 4 weeks, and 8 weeks) include the perceived threat of Alzheimer disease, dementia awareness, and self-efficacy. This project was funded in August 2022. Data collection began in 2023 and is projected to be completed in 2025. Study findings will reveal the feasibility of delivering an 8-week multidomain health education intervention for primary prevention of dementia in midlife and will provide preliminary evidence of mechanisms of change. ClinicalTrials.gov NCT05599425; https://clinicaltrials.gov/study/NCT05599425. DERR1-10.2196/60395.

Sections du résumé

BACKGROUND BACKGROUND
A total of 12 modifiable risk factors account for 40% of dementia cases globally, yet population adherence to health behaviors associated with these factors is low. Midlife is a critical window for dementia prevention, as brain pathology often begins to accumulate years or decades before the onset of symptoms. Although multidomain behavioral interventions have been efficacious in reducing the risk of cognitive decline, adherence is low. Intrapersonal factors, such as health beliefs, are known mediators of the relationship between knowledge and health behavior.
OBJECTIVE OBJECTIVE
In keeping with stage I of the National Institutes of Health (NIH) Stage Model for Behavioral Intervention Development, this study will use mixed methods to (1) develop an enhanced health education intervention, including an explanatory method for communicating information about dementia risk and personal health beliefs, and (2) conduct a pilot randomized controlled trial (n=20 per intervention arm) over 8 weeks to assess the feasibility of delivering the enhanced intervention versus basic health education alone.
METHODS METHODS
Phase 1 will involve focus groups and individual qualitative interviews. Focus groups will be analyzed using (1) a descriptive framework matrix analysis and (2) interpretive data review by the research team. Individual qualitative interviews will be coded using applied thematic analysis using a phenomenographic approach. Phase 2 will involve a pilot randomized controlled trial. Proximal outcomes (measured at baseline, 4 weeks, and 8 weeks) include the perceived threat of Alzheimer disease, dementia awareness, and self-efficacy.
RESULTS RESULTS
This project was funded in August 2022. Data collection began in 2023 and is projected to be completed in 2025.
CONCLUSIONS CONCLUSIONS
Study findings will reveal the feasibility of delivering an 8-week multidomain health education intervention for primary prevention of dementia in midlife and will provide preliminary evidence of mechanisms of change.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT05599425; https://clinicaltrials.gov/study/NCT05599425.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
DERR1-10.2196/60395.

Identifiants

pubmed: 39412840
pii: v13i1e60395
doi: 10.2196/60395
doi:

Banques de données

ClinicalTrials.gov
['NCT05599425']

Types de publication

Journal Article Randomized Controlled Trial Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e60395

Informations de copyright

©Laura E Korthauer, Rochelle K Rosen, Geoffrey Tremont, Jennifer D Davis. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 16.10.2024.

Auteurs

Laura E Korthauer (LE)

Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, United States.
Department of Psychiatry, Rhode Island Hospital, Providence, RI, United States.

Rochelle K Rosen (RK)

Center for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, RI, United States.
School of Public Health, Brown University, Providence, RI, United States.

Geoffrey Tremont (G)

Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, United States.

Jennifer D Davis (JD)

Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, United States.
Department of Psychiatry, Rhode Island Hospital, Providence, RI, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH